Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 5,400 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its position in IQVIA Holdings Inc. by 15.2%, selling 5,400 shares during the first quarter, leaving them with 30,056 shares valued at approximately $5.3 million.
• In contrast, several large investors increased their holdings in IQVIA, including Caitong International Asset Management which raised its stake by 99.3%, and National Pension Service which grew its stake by 10.6%.
• Recent earnings reports showed IQVIA generated $4.02 billion in revenue and reported earnings per share of $2.81, exceeding analyst expectations.

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,056 shares of the medical research company's stock after selling 5,400 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in IQVIA were worth $5,299,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. American National Bank & Trust purchased a new position in IQVIA during the 1st quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd lifted its position in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC lifted its position in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC purchased a new position in IQVIA during the 1st quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. lifted its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV stock traded down $4.62 during trading hours on Thursday, reaching $187.42. The company had a trading volume of 224,941 shares, compared to its average volume of 1,961,970. The business has a fifty day moving average price of $172.49 and a 200-day moving average price of $168.67. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The firm has a market cap of $31.86 billion, a PE ratio of 27.13, a price-to-earnings-growth ratio of 2.11 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the business posted $2.64 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on IQV shares. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and lowered their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Citigroup reissued a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. UBS Group raised their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, Evercore ISI raised their price objective on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $228.62.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.